Nothing said here yet.
to join the conversation.
| Morais Mark A.Chief Operating Officer | Sell | 3,149 | $53.1K | Wed, Sep 9 |
| Russell Carrie ElizabethInterim CAO | Sell | 246 | $4.1K | Wed, Sep 9 |
| Morais Mark A.Chief Operating Officer | Sell | 4,892 | $89.0K | Wed, Aug 19 |
Clinical research company Fortrea Holdings (NASDAQ:FTRE) reported Q3 2026 results beating Wall Street’s revenue expectations, but sales fell by 1.4% year on year to $691.5 million.
Fortrea Holdings reported Q3 2026 revenue of US$691.5 million and returned to a modest profit, while also narrowing and raising full year 2026 revenue guidance to a range of US$2.665 billion to US$2.69 billion.
Fortrea Holdings now carries a modestly higher fair value estimate, moving from US$20.55 to US$21.71 per share, as analysts refresh their models.
Fortrea came into this Q3 2026 report with a stock that had quietly rebuilt some confidence over the past three months, only to see that mood crack with a one day slide of almost 8% to US$21.29.
Fortrea (NASDAQ:FTRE) reported third-quarter 2026 revenue of $691.5 million, down 1.4% from a year earlier but up 2.0% sequentially, as the contract research organization cited improving demand, stronger operational execution and continued cost discipline.
Clinical research company Fortrea Holdings (NASDAQ:FTRE) announced better-than-expected revenue in Q3 2026, but revenue fell by 1.4% year on year to $691.5 million.
Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of +16.67% and +3.18%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Clinical research company Fortrea Holdings (NASDAQ:FTRE) will be announcing earnings results this Thursday before the bell. Here’s what to expect.